Needham Downgrades Boston Scientific to Hold, Maintains Price Target to $86
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Mike Matson has downgraded Boston Scientific (NYSE:BSX) from Buy to Hold, while maintaining the price target at $86.
October 18, 2024 | 9:32 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst Mike Matson downgraded Boston Scientific from Buy to Hold, maintaining the price target at $86. This suggests a neutral outlook on the stock.
The downgrade from Buy to Hold indicates that the analyst no longer sees significant upside potential in the stock, suggesting a neutral outlook. However, the maintained price target of $86 implies that the analyst believes the stock is fairly valued at current levels. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100